IL-27R alpha/TCCR Protein, Mouse (HEK293, His)

IL-27R alpha(Interleukin 27 receptor alpha) is a subunit of the interleukin-27 receptor, an inflammatory cytokine that possesses extensive immunological functions. IL-27R alphacan be used as a natural IL-27 antagonist^[1]. IL-27R alpha/TCCR Protein, Mouse (HEK293, His) is a recombinant protein with a His label that consists of 482 amino acids (G29-K510) and is produced by HEK293 cells.

IL-27Rα is specific for IL-27 and is primarily expressed on the cell surface of inflammatory cells, including T, B, and NK lymphocytes, neutrophils, monocytes, and mast cells, although it is found at lower levels in macrophages, hepatocytes, keratinocytes, and endothelial cells^[2].
The amino acid sequence of human IL-27R alpha protein has low homology for mouse IL-27R alpha protein.
IL-27Rα (WSX-1) and gp130 compose the IL-27 receptor-signaling complex. Binding of IL-27 to its heterodimeric receptor complex leads to the intracellular recruitment and activation of the Janus kinase (JAK)/STAT-1 and STAT-3 pathways, suppress the expression of inflammatory cytokines^[3].
IL-27R alpha is a class I cytokine receptor with homology to gp130 of IL-6R and to IL-12R families. IL-27R alpha can be used as a natural IL-27 antagonist^[1]. IL-27R alpha can be used as an independent prognostic aGVHD biomarker^[4]. IL-27/IL-27R alpha also plays an important role in the down-regulation of airway hyper-reactivity and lung inflammation during the development of allergic asthma through its suppressive effect on cytokine production^[5]. IL-27/IL-27RA signaling can suppress the expression of inflammatory cytokines, IL-6 and IL-8, induced by LPS stimulation, leading to phosphorylation of STAT1 and STAT3^[6].

Immobilized IL-27 (HY-P72554) at 5 μg/mL (100 μL/well) can bind Biotinylated Mouse IL-27 Ra Protein.The ED₅₀ for this effect is 0.4573 μg/mL.

• 
  Immobilized IL-27 (HY-P72554) at 5 μg/mL (100 μL/well) can bind Biotinylated Mouse IL-27 Ra Protein.The ED₅₀ for this effect is 0.4573 μg/mL.

Mouse

HEK293

C-His

O70394 (G29-K510)

50931  [NCBI]

Partial

GSPGPLQCYSVGPLGILNCSWEPLGDLETPPVLYHQSQKYHPNRVWEVKVPSKQSWVTIPREQFTMADKLLIWGTQKGRPLWSSVSVNLETQMKPDTPQIFSQVDISEEATLEATVQWAPPVWPPQKVLICQFRYKECQAETWTRLEPQLKTDGLTPVEMQNLEPGTCYQVSGRCQVENGYPWGEWSSPLSFQTPFLDPEDVWVSGTVCETSGKRAALLVWKDPRPCVQVTYTVWFGAGDITTTQEEVPCCKSPVPAWMEWAVVSPGNSTSWVPPTNLSLVCLAPESAPCDVGVSSADGSPGIKVTWKQGTRKPLEYVVDWAQDGDSLDKLNWTRLPPGNLSTLLPGEFKGGVPYRITVTAVYSGGLAAAPSVWGFREELVPLAGPAVWRLPDDPPGTPVVAWGEVPRHQLRGQATHYTFCIQSRGLSTVCRNVSSQTQTATLPNLHLGSFKLWVTVSTVAGQGPPGPNLSLHLPDNRIRWK

Approximately 54.6 kDa

≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4, 5% trehalose, 5% mannitol and 0.01% Tween 80.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Liu S, et al. Soluble interleukin-27 receptor alpha is a valuable prognostic biomarker for acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Sci Rep. 2018 Jul 9;8(1):10328.  [Content Brief]

  [2]. Fabbi M, et al. Dual Roles of IL-27 in Cancer Biology and Immunotherapy. Mediators Inflamm. 2017;2017:3958069.  [Content Brief]

  [3]. Rousseau F, et al. IL-27 structural analysis demonstrates similarities with ciliary neurotrophic factor (CNTF) and leads to the identification of antagonistic variants. Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19420-5.  [Content Brief]

  [4]. Miyazaki Y, et al. Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-1-deficient mice. J Immunol. 2005 Aug 15;175(4):2401-7.  [Content Brief]

  [5]. Lo HC, et al. IL-27/IL-27RA signaling may modulate inflammation and progression of benign prostatic hyperplasia via suppressing the LPS/TLR4 pathway. Transl Cancer Res. 2020 Aug;9(8):4618-4634.  [Content Brief]